PE20120184A1 - Derivados del pirrolo[2,3-b]piridina para la inhibicion de las proteinas quinasas raf - Google Patents
Derivados del pirrolo[2,3-b]piridina para la inhibicion de las proteinas quinasas rafInfo
- Publication number
- PE20120184A1 PE20120184A1 PE2011001620A PE2011001620A PE20120184A1 PE 20120184 A1 PE20120184 A1 PE 20120184A1 PE 2011001620 A PE2011001620 A PE 2011001620A PE 2011001620 A PE2011001620 A PE 2011001620A PE 20120184 A1 PE20120184 A1 PE 20120184A1
- Authority
- PE
- Peru
- Prior art keywords
- pyridine
- pyrrolo
- difluoro
- carbonyl
- phenyl
- Prior art date
Links
- 102000001253 Protein Kinase Human genes 0.000 title abstract 2
- 108060006633 protein kinase Proteins 0.000 title abstract 2
- MVXVYAKCVDQRLW-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine Chemical class C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- -1 [3- (5-CYANO-1H-PYRROLO [2,3-b] PYRIDINE-3-CARBONYL) -2,4-DIFLUORO-PHENYL] -AMIDE PROPANE-1-SULPHONIC ACID Chemical compound 0.000 abstract 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 abstract 2
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 208000032612 Glial tumor Diseases 0.000 abstract 1
- 206010018338 Glioma Diseases 0.000 abstract 1
- 102000018471 Proto-Oncogene Proteins B-raf Human genes 0.000 abstract 1
- 108010091528 Proto-Oncogene Proteins B-raf Proteins 0.000 abstract 1
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 abstract 1
- 208000024770 Thyroid neoplasm Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1
- KQBOUIWARNMUDQ-UHFFFAOYSA-N pyrrolidin-1-ium-1-sulfonate Chemical compound OS(=O)(=O)N1CCCC1 KQBOUIWARNMUDQ-UHFFFAOYSA-N 0.000 abstract 1
- 201000002510 thyroid cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE PIRROLO[2,3-b]PIRIDINA TAL COMO: ACIDO PROPANO-1-SULFONICO DE {2,4-DIFLUORO-3-[5-(2-METOXI-PIRIMIDIN-5-IL)-1H-PIRROLO[2,3-b]PIRIDINA-3-CARBONIL]-FENIL}-AMIDA; ACIDO PROPANO-1-SULFONICO DE [3-(5-CIANO-1H-PIRROLO[2,3-b]PIRIDINA-3-CARBONIL)-2,4-DIFLUORO-FENIL]-AMIDA; ACIDO PROPANO-1-SULFONICO DE [3-(5-CIANO-1H-PIRROLO[2,3-b]PIRIDINA-3-CARBONIL)-2-FLUORO-FENIL]-AMIDA; N-[3-(5-CIANO-1H-PIRROLO[2,3-b]PIRIDINA-3-CARBONIL)-2,4-DIFLUORO-FENIL]-2,5-DIFLUORO-BENCENOSULFONAMIDA; N-[3-(5-CIANO-1H-PIRROLO[2,3-b]PIRIDINA-3-CARBONIL)-2,4-DIFLUORO-FENIL]-3-FLUORO-BENCENO-SULFONAMIDA; ACIDO PIRROLIDINA-1-SULFONICO DE [3-(5-CIANO-1H-PIRROLO[2,3-b]PIRIDINA-3-CARBONIL)-2,4-DIFLUORO-FENIL]-AMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LAS PROTEINA QUINASAS RAF COMO A-RAF, B-RAF Y c-RAF-1 SIENDO UTILES EN EL TRATAMIENTO DE MELANOMA, GLIOMA, CANCER COLORRECTAL, CANCER DE TIROIDES
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15939609P | 2009-03-11 | 2009-03-11 | |
| US15940209P | 2009-03-11 | 2009-03-11 | |
| US15939009P | 2009-03-11 | 2009-03-11 | |
| US15939509P | 2009-03-11 | 2009-03-11 | |
| US15940009P | 2009-03-11 | 2009-03-11 | |
| US15940609P | 2009-03-11 | 2009-03-11 | |
| US15939209P | 2009-03-11 | 2009-03-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20120184A1 true PE20120184A1 (es) | 2012-03-28 |
Family
ID=42199540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011001620A PE20120184A1 (es) | 2009-03-11 | 2010-03-10 | Derivados del pirrolo[2,3-b]piridina para la inhibicion de las proteinas quinasas raf |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8901301B2 (es) |
| EP (1) | EP2406259A1 (es) |
| JP (1) | JP2012520307A (es) |
| KR (1) | KR101663339B1 (es) |
| CN (1) | CN102421776A (es) |
| AR (1) | AR075812A1 (es) |
| AU (1) | AU2010224245B2 (es) |
| BR (1) | BRPI1011515A2 (es) |
| CA (1) | CA2755045A1 (es) |
| CO (1) | CO6620074A2 (es) |
| CR (1) | CR20110476A (es) |
| EC (1) | ECSP11011313A (es) |
| MA (1) | MA33181B1 (es) |
| MX (1) | MX2011009489A (es) |
| MY (1) | MY161861A (es) |
| NI (1) | NI201100168A (es) |
| NO (1) | NO20111241A1 (es) |
| PE (1) | PE20120184A1 (es) |
| RU (1) | RU2011141123A (es) |
| SG (2) | SG10201402977WA (es) |
| TW (1) | TW201036973A (es) |
| WO (1) | WO2010104945A1 (es) |
| ZA (1) | ZA201106599B (es) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| SG183036A1 (en) | 2007-07-17 | 2012-08-30 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| WO2009143018A2 (en) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| JP2012509342A (ja) | 2008-11-20 | 2012-04-19 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | 置換ピロロ［２，３−ｂ］−ピリジンおよび−ピラジン |
| CN102361870B (zh) | 2009-04-03 | 2015-11-25 | 豪夫迈罗氏公司 | 丙烷-1-磺酸{3-[5-(4-氯-苯基)-1H-吡咯并[2,3-b]吡啶-3-羰基]-2,4-二氟-苯基}-酰胺组合物及其用途 |
| MX2012005284A (es) | 2009-11-06 | 2012-06-28 | Plexxikon Inc | Compuestos y metodos para la modulacion de cinasas. e indicaciones para ello. |
| BR112012011792A2 (pt) | 2009-11-18 | 2015-10-13 | Plexxikon Inc | "compostos e métodos para modulação de quinases, e indicações para os mesmos" |
| CA2784393A1 (en) | 2009-12-23 | 2011-06-30 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| TWI619713B (zh) | 2010-04-21 | 2018-04-01 | 普雷辛肯公司 | 用於激酶調節的化合物和方法及其適應症 |
| WO2011143646A1 (en) | 2010-05-14 | 2011-11-17 | OSI Pharmaceuticals, LLC | Fused bicyclic kinase inhibitors |
| AR081039A1 (es) | 2010-05-14 | 2012-05-30 | Osi Pharmaceuticals Llc | Inhibidores biciclicos fusionados de quinasa |
| WO2012075324A1 (en) | 2010-12-02 | 2012-06-07 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods for treating a tumor using an antibody that specifically binds hmw-maa |
| JP5941069B2 (ja) * | 2011-02-07 | 2016-06-29 | プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． | キナーゼ調節のための化合物および方法、ならびにそれに対する適応症 |
| WO2012149547A1 (en) * | 2011-04-28 | 2012-11-01 | Duke University | Methods of treating hemoglobinopathies |
| CN103917235A (zh) | 2011-05-17 | 2014-07-09 | 普莱希科公司 | 激酶调节及其适应症 |
| US9988687B2 (en) * | 2011-09-20 | 2018-06-05 | The George Washington Univeristy | Companion diagnostics for cancer and screening methods to identify companion diagnostics for cancer based on splicing variants |
| US9249110B2 (en) | 2011-09-21 | 2016-02-02 | Neupharma, Inc. | Substituted quinoxalines as B-raf kinase inhibitors |
| US20130172375A1 (en) | 2011-12-13 | 2013-07-04 | Hoffmann-La Roche Inc. | Pharmaceutical composition |
| US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
| US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| BR112014032346A2 (pt) | 2012-06-26 | 2017-06-27 | Del Mar Pharmaceuticals | métodos para tratamento de malignidades resistentes ao inibidor de tirosina-quinase em pacientes com polimorfismos genéticos ou desregulações de ahi1 mutações empregando dianidrogalactitol, diacetildianidrogalactitol, dibromodulcitol, ou análogos ou derivados destes |
| TWI601725B (zh) | 2012-08-27 | 2017-10-11 | 加拓科學公司 | 取代的氮雜吲哚化合物及其鹽、組合物和用途 |
| CA2883894C (en) | 2012-09-06 | 2020-08-18 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| WO2014081760A1 (en) | 2012-11-20 | 2014-05-30 | Duke University | Methods of treating hemoglobinopathies |
| RS57117B1 (sr) | 2012-12-21 | 2018-06-29 | Plexxikon Inc | Jedinjenja i metode modulacije kinaze i povezane indikacije |
| SG11201506687RA (en) | 2013-03-15 | 2015-09-29 | Plexxikon Inc | Heterocyclic compounds and uses thereof |
| US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
| CN105492011A (zh) | 2013-04-08 | 2016-04-13 | 丹尼斯·M·布朗 | 不理想给药化学化合物的治疗增效 |
| RU2015149937A (ru) | 2013-05-30 | 2017-07-06 | Плексксикон Инк. | Соединения для модулирования киназы и показания к их применению |
| EP3094736A4 (en) | 2014-01-14 | 2017-10-25 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms |
| WO2015134536A1 (en) | 2014-03-04 | 2015-09-11 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| JP6832846B2 (ja) | 2014-09-15 | 2021-02-24 | プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． | ヘテロ環化合物およびその用途 |
| WO2016057367A1 (en) | 2014-10-06 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
| WO2016164641A1 (en) | 2015-04-08 | 2016-10-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| MX386963B (es) | 2015-05-06 | 2025-03-19 | Daiichi Sankyo Inc | Formas sólidas de quinasas que modulan un compuesto. |
| CN107531706A (zh) | 2015-05-06 | 2018-01-02 | 普莱希科公司 | 调节激酶的1H‑吡咯并[2,3‑b]吡啶衍生物的合成 |
| WO2017019804A2 (en) | 2015-07-28 | 2017-02-02 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| MY195977A (en) | 2015-09-21 | 2023-02-27 | Plexxikon Inc | Heterocyclic Compounds and uses Thereof |
| SG11201804711RA (en) | 2015-12-07 | 2018-07-30 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| US10160747B2 (en) | 2016-03-16 | 2018-12-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| TW201815766A (zh) | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症 |
| CA3047580A1 (en) | 2016-12-23 | 2018-07-26 | Plexxikon Inc. | Compounds and methods for cdk8 modulation and indications therefor |
| MX393780B (es) | 2017-01-17 | 2025-03-24 | Heparegenix Gmbh | Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos |
| US10577366B2 (en) | 2017-03-20 | 2020-03-03 | Plexxikon Inc. | Crystalline forms of a compound that inhibits bromodomain |
| US10428067B2 (en) | 2017-06-07 | 2019-10-01 | Plexxikon Inc. | Compounds and methods for kinase modulation |
| US10435404B2 (en) | 2017-07-25 | 2019-10-08 | Plexxikon Inc. | Formulations of a compound modulating kinases |
| WO2019075243A1 (en) | 2017-10-13 | 2019-04-18 | Plexxikon Inc. | SOLID FORMS OF A COMPOUND FOR MODULATING KINASES |
| AU2018354423B2 (en) | 2017-10-27 | 2024-11-07 | Plexxikon Inc. | Formulations of a compound modulating kinases |
| ES3000465T3 (en) | 2018-01-31 | 2025-02-28 | Heparegenix Gmbh | Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| CA3094336A1 (en) | 2018-03-20 | 2019-09-26 | Plexxikon Inc. | Compounds and methods for ido and tdo modulation, and indications therefor |
| GB201809460D0 (en) * | 2018-06-08 | 2018-07-25 | Crt Pioneer Fund Lp | Salt form |
| US11731968B2 (en) | 2018-06-21 | 2023-08-22 | Heparegenix Gmbh | Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| CN112424201B (zh) | 2018-07-16 | 2024-04-02 | 海帕瑞吉尼克斯股份有限公司 | 促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂 |
| JP7636646B2 (ja) | 2019-04-09 | 2025-02-27 | オプナ バイオ ソシエテ アノニム | Ｅｐ３００またはｃｂｐの調節のための縮合アジンおよびその適応 |
| AU2021207236A1 (en) | 2020-01-15 | 2022-08-11 | Heparegenix Gmbh | 3-benzoyl-1h-pyrrolo[2,3-b]pyridine derivatives as MKK4 inhibitors for treating liver diseases |
| AU2021261383A1 (en) | 2020-04-23 | 2022-11-17 | Opna Bio SA | Compounds and methods for CD73 modulation and indications therefor |
| CN115605460A (zh) | 2020-04-29 | 2023-01-13 | 普莱希科公司（Us） | 杂环化合物的合成 |
| TW202227068A (zh) | 2020-08-21 | 2022-07-16 | 美商普雷辛肯公司 | 組合藥物療法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1534340E (pt) * | 2002-09-06 | 2012-03-13 | Cerulean Pharma Inc | Polímeros à base de ciclodextrina para a administração de medicamentos ligados por ligação covalente |
| DK2395004T3 (en) * | 2005-06-22 | 2016-03-21 | Plexxikon Inc | Pyrrolo [2,3-b] pyridine derivatives as protein kinase inhibitors |
| PE20081581A1 (es) | 2006-12-21 | 2008-11-12 | Plexxikon Inc | COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA |
-
2010
- 2010-03-10 RU RU2011141123/04A patent/RU2011141123A/ru unknown
- 2010-03-10 MA MA34228A patent/MA33181B1/fr unknown
- 2010-03-10 US US12/721,496 patent/US8901301B2/en active Active
- 2010-03-10 SG SG10201402977WA patent/SG10201402977WA/en unknown
- 2010-03-10 CN CN2010800206771A patent/CN102421776A/zh active Pending
- 2010-03-10 PE PE2011001620A patent/PE20120184A1/es not_active Application Discontinuation
- 2010-03-10 SG SG2011063914A patent/SG174257A1/en unknown
- 2010-03-10 AR ARP100100731A patent/AR075812A1/es unknown
- 2010-03-10 BR BRPI1011515A patent/BRPI1011515A2/pt not_active Application Discontinuation
- 2010-03-10 MY MYPI2011004233A patent/MY161861A/en unknown
- 2010-03-10 EP EP10708681A patent/EP2406259A1/en not_active Withdrawn
- 2010-03-10 AU AU2010224245A patent/AU2010224245B2/en active Active
- 2010-03-10 KR KR1020117023712A patent/KR101663339B1/ko not_active Expired - Fee Related
- 2010-03-10 JP JP2011554147A patent/JP2012520307A/ja not_active Withdrawn
- 2010-03-10 CA CA2755045A patent/CA2755045A1/en not_active Abandoned
- 2010-03-10 WO PCT/US2010/026816 patent/WO2010104945A1/en not_active Ceased
- 2010-03-10 MX MX2011009489A patent/MX2011009489A/es not_active Application Discontinuation
- 2010-03-10 TW TW099106990A patent/TW201036973A/zh unknown
-
2011
- 2011-08-09 EC EC2011011313A patent/ECSP11011313A/es unknown
- 2011-09-06 CR CR20110476A patent/CR20110476A/es unknown
- 2011-09-08 ZA ZA2011/06599A patent/ZA201106599B/en unknown
- 2011-09-09 NI NI201100168A patent/NI201100168A/es unknown
- 2011-09-12 CO CO11117856A patent/CO6620074A2/es not_active Application Discontinuation
- 2011-09-13 NO NO20111241A patent/NO20111241A1/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP11011313A (es) | 2011-10-31 |
| CN102421776A (zh) | 2012-04-18 |
| ZA201106599B (en) | 2014-02-26 |
| CO6620074A2 (es) | 2013-02-15 |
| CR20110476A (es) | 2012-01-04 |
| WO2010104945A1 (en) | 2010-09-16 |
| KR20110125670A (ko) | 2011-11-21 |
| NO20111241A1 (no) | 2011-09-28 |
| EP2406259A1 (en) | 2012-01-18 |
| US8901301B2 (en) | 2014-12-02 |
| AU2010224245B2 (en) | 2016-07-21 |
| KR101663339B1 (ko) | 2016-10-06 |
| AR075812A1 (es) | 2011-04-27 |
| MA33181B1 (fr) | 2012-04-02 |
| MY161861A (en) | 2017-05-15 |
| CA2755045A1 (en) | 2010-09-16 |
| BRPI1011515A2 (pt) | 2016-03-29 |
| AU2010224245A1 (en) | 2011-09-29 |
| RU2011141123A (ru) | 2013-04-20 |
| TW201036973A (en) | 2010-10-16 |
| US20100286178A1 (en) | 2010-11-11 |
| SG10201402977WA (en) | 2014-09-26 |
| MX2011009489A (es) | 2011-10-11 |
| JP2012520307A (ja) | 2012-09-06 |
| NI201100168A (es) | 2012-01-11 |
| SG174257A1 (en) | 2011-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20120184A1 (es) | Derivados del pirrolo[2,3-b]piridina para la inhibicion de las proteinas quinasas raf | |
| EA201200951A1 (ru) | Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения | |
| EA201101585A1 (ru) | 3-(1,2,3-триазол-4-ил)пирроло[2,3-b]пиридинпроизводные | |
| PE20120518A1 (es) | Compuestos derivados de pirrolopiridina como moduladores de quinasas | |
| EA201101192A1 (ru) | Фармацевтическая композиция, включающая производные глюкопиранозилдифенилметана, фармацевтическая дозированная форма, содержащая указанные производные, способ их получения и применения для улучшения гликемического контроля у пациентов | |
| CL2007001710A1 (es) | Compuestos derivados de amino-pirazolopiridina sustituidos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como tumores, artritis reumatoide, enfermedades de crecimiento vascular desregulado, entre otras. | |
| UY30892A1 (es) | Inhibidores de la actividad akt | |
| CL2008000670A1 (es) | Compuestos derivados de tiazolidindionas y oxazolidindionas sustituidas; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis reumatoide, epoc, cancer, entre otras. | |
| EA201290103A1 (ru) | Гетероциклические соединения и их использование | |
| IL206704A0 (en) | Fused heterocyclic derivatives and methods of use as c-met inhibitors | |
| IL206930A0 (en) | Fused pyridines active as inhibitors of c-met | |
| EP4406557A3 (en) | Materials and methods for improving gastrointestinal function | |
| EA201290255A1 (ru) | Способы и композиции для лечения рака | |
| EA201201081A1 (ru) | Производные гетарил[1,8]нафтиридина | |
| MY167575A (en) | Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases | |
| MX352927B (es) | Derivados de 1h-pirrolo [2,3-b] piridina y su uso como inhibidores de quinasa. | |
| EA200800726A1 (ru) | Введение ингибиторов дипептидилпептидазы | |
| MX385217B (es) | Antagonistas de actriib y dosificación y usos de los mismos. | |
| HUE049886T2 (hu) | Tumorspecifikus neoantigéneket tartalmazó készítmények, tumorok kezelésében történõ alkalmazásra | |
| IL215074A0 (en) | Substituted imidazo[1,2-a]pyridine derivatives, pharmaceutical compositions, and methods of use as beta-secretase inhibitors | |
| EA201101399A1 (ru) | Гетероциклические соединения в качестве ингибиторов аутотаксина | |
| CL2010001474A1 (es) | Compuestos derivados de tiofeno o tiazol sustituidos, inhibidores de pi3k; composicion farmaceutica; utiles en el tratamiento del cancer, inflamacion y en el tratamiento de trastornos cardiovasculares. | |
| EP2617721A4 (en) | NEW HETEROCYCLIC COMPOUND AND COMPOSITION FOR THE TREATMENT OF INFLAMMATORY DISORDERS THEREWITH | |
| PH12013501754A1 (en) | Triazolopyridine compounds as pim kinase inhibitors | |
| CL2011000846A1 (es) | Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |